FN1 and neoplasm: In addition to the observed suppression of CAF-generated FN, we predict that in humans, the BsAb might gain additional antitumor efficacy by acting on activated cell types within the tumor that are known to gain expression of αvβ3/α5β1, including angiogenic endothelial cells and tumor-associated macrophages.